Apollon Formularies Plc Resignation of Non-Executive Director

 
TIDMAPOL 
 
Apollon Formularies plc (AQSE: APOL, "Apollon" or the "Company"), a UK based 
international medical cannabis pharmaceutical company trading on AQSE Growth 
Market, announces the resignation of Nicholas (Nick) Ingrassia as a Non 
-Executive Director with immediate effect to focus on his other business 
commitments. 
 
Nick has sat on the Board of Apollon since it went public on the Aquis Growth 
market in April 2021. 
 
Nick Ingrassia,  of Apollon Formularies, commented "It has been an honour and a 
pleasure to serve on the Apollon board alongside a group of such brilliant and 
dedicated directors. I believe Apollon has built an exciting intellectual 
property portfolio and brand. With a renewed outlook following its geographic 
shift, I believe the business is well positioned for success despite the 
challenging market environment in the medical cannabis space." 
 
Stene Jacobs, COO of Apollon Formularies, commented,"We extend our heartfelt 
appreciation to Nick for his service and dedication during his tenure as a 
valued member of our board. While we understand and respect his decision to step 
down, his impact will continue to resonate in our ongoing business. We extend 
our best wishes for his future endeavours." 
 
 The Directors of the Company accept responsibility for the contents of this 
announcement. 
 
- End - 
 
Apollon Formularies 
 
 Stene Jacobs                        stene@apollon.org.uk 
 
 Peterhouse Capital Limited (Corporate Adviser) 
 
Tel:                                         +44 207 220 9795 
 
Guy Miller                             gm@peterhousecapital.com 
 
 Blytheweigh (Financial PR/IR-London) 
 
Tel:                                         +44 207 138 3204 
 
Tim Blythe                            tim.blythe@blytheweigh.com 
 
Megan Ray                           megan.ray@blytheweigh.com 
 
About Apollon Formularies plc 
 
Apollon Formularies is an international bio-medical pharmaceutical company 
specialising in cutting edge research and treatment of patients with cancer and 
chronic pain. 
 
Apollon is federally legal, licensed in Jamaica, holds a suite of licences which 
allow the company to work with full spectrum oils inclusive of high levels of 
THC. Apollon's formulations are available by prescription to any licensed 
Jamaican doctor for their patients and for export to any country allowing legal 
import. 
 
Apollon is a publicly traded company listed on the Aquis Growth Market in London 
(AQSE: APOL) 
 
This information was brought to you by Cision http://news.cision.com 
https://news.cision.com/apollon-formularies-plc/r/resignation-of-non-executive-director,c3813149 
 
 
END

(END) Dow Jones Newswires

August 03, 2023 05:51 ET (09:51 GMT)

Apollon Formularies (AQSE:APOL)
Historical Stock Chart
From Mar 2024 to Apr 2024